Skip to content

Sentinel node Navigation surgery in early esophageal Adenocarcinoma Patients with lymph node involvement: SNAP-IV study

Sentinel node Navigation surgery in early esophageal Adenocarcinoma Patients with lymph node involvement: SNAP-IV study - SNAP-IV study

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON50168
Enrollment
5
Registered
2020-03-24
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early esophageal adenocarcinoma

Interventions

Patients will be subjected to a SN procedure. One day before SN procedure patients will undergo an upper endoscopy for submucosal injection of the radioactive tracer (technetium) and indocyanine gre

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Esophageal adenocarcinoma, clinically staged as T1N1M0 with an indication for esophagectomy Clinical condition allowing endoscopy and surgery Older than 18 years at time of informed consent Written informed consent

Exclusion criteria

Exclusion criteria: Esophageal squamous cell carcinoma Clinically staged as T>1, N>1 and/or M1 Neoadjuvant (chemo)radiation therapy Known allergy for the radioactive tracer (technetium) or dye (indocyanine green) Comorbidity precluding endoscopy and/or surgery Refusing or unable to provide written informed consent

Design outcomes

Secondary

MeasureTime frame
The secondary outcomes for this study are: 1) Percentage of patients with a detectable SN, either on SPECT/CT, probe-based or with a NIR camera. 2) Number of resected SN, location documented. 3) Ratio of number of dissected SNs and number of detected SNs on imaging. 4) Number of tumor-positive dissected SNs, subdivided per LN station. 5) Ratio of number of tumor-positive dissected SNs and number of detected SNs on imaging. 6) Concordance of pre-operative SPECT/CT and perioperative probe-based and ICG-based detection of SNs. 7) Additional yield of ICG-based SN detection over technetium SN detection. 8) Number of detectable SNs, either on SPECT/CT, probe-based or with a NIR camera, which could not be dissected during surgery, location and reason documented. 9) Procedure time of SNNS. 10) Incidence and severity of all adverse events.

Primary

MeasureTime frame
The primary outcome for this study is the percentage of patients in whom tumor-positive LN(s) are detected as SN(s), either on SPECT/CT, probe-based or with a NIR camera.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)